Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

1,184 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. Atrial Fibrillation Aspirin and Anticoagulation.
Gulløv AL, Koefoed BG, Petersen P. Gulløv AL, et al. Arch Intern Med. 1999 Jun 28;159(12):1322-8. doi: 10.1001/archinte.159.12.1322. Arch Intern Med. 1999. PMID: 10386508 Clinical Trial.
During treatment with mini-dose warfarin, warfarin plus aspirin, aspirin, and adjusted-dose warfarin, the annual rate of major bleeding was 0.8%, 0.3%, 1.4%, and 1.1%, respectively (P = .20). After 3 years of treatment the cumulative rate of any bleeding was 24.7%, 24.4%, …
During treatment with mini-dose warfarin, warfarin plus aspirin, aspirin, and adjusted-dose warfarin, the annual rate of major bleeding was …
Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials.
Gomberg-Maitland M, Wenger NK, Feyzi J, Lengyel M, Volgman AS, Petersen P, Frison L, Halperin JL. Gomberg-Maitland M, et al. Eur Heart J. 2006 Aug;27(16):1947-53. doi: 10.1093/eurheartj/ehl103. Epub 2006 Jun 14. Eur Heart J. 2006. PMID: 16774980 Clinical Trial.
Women were older, on average, than men, 73.4+/-8.0 vs. 69.8+/-9.0 years (P<0.0001). More women were >75-years old and women had more risk factors than men had (P<0.0001). ...Major bleeding rates were similar (P=0.766) but women experienced more overa …
Women were older, on average, than men, 73.4+/-8.0 vs. 69.8+/-9.0 years (P<0.0001). More women were >75-years old and women had …
Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators.
van Walraven C, Hart RG, Connolly S, Austin PC, Mant J, Hobbs FD, Koudstaal PJ, Petersen P, Perez-Gomez F, Knottnerus JA, Boode B, Ezekowitz MD, Singer DE. van Walraven C, et al. Stroke. 2009 Apr;40(4):1410-6. doi: 10.1161/STROKEAHA.108.526988. Epub 2009 Jan 29. Stroke. 2009. PMID: 19182090
Compared with placebo, the relative benefit of AP for preventing ischemic stroke decreased significantly as patients aged (P=0.01). ...
Compared with placebo, the relative benefit of AP for preventing ischemic stroke decreased significantly as patients aged (P=0.01). . …
Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial.
Albers GW, Diener HC, Frison L, Grind M, Nevinson M, Partridge S, Halperin JL, Horrow J, Olsson SB, Petersen P, Vahanian A; SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Albers GW, et al. JAMA. 2005 Feb 9;293(6):690-8. doi: 10.1001/jama.293.6.690. JAMA. 2005. PMID: 15701910 Clinical Trial.
The primary event rate with ximelagatran was 1.6% per year and with warfarin was 1.2% per year (absolute difference, 0.45% per year; 95% confidence interval, -0.13% to 1.03% per year; P<.001 for the predefined noninferiority hypothesis). When all-cause mortality was inc …
The primary event rate with ximelagatran was 1.6% per year and with warfarin was 1.2% per year (absolute difference, 0.45% per year; 95% con …
Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin.
Gage BF, van Walraven C, Pearce L, Hart RG, Koudstaal PJ, Boode BS, Petersen P. Gage BF, et al. Circulation. 2004 Oct 19;110(16):2287-92. doi: 10.1161/01.CIR.0000145172.55640.93. Epub 2004 Oct 11. Circulation. 2004. PMID: 15477396
New approaches to anticoagulation in atrial fibrillation.
Petersen P. Petersen P. Curr Cardiol Rep. 2004 Sep;6(5):354-64. doi: 10.1007/s11886-004-0038-3. Curr Cardiol Rep. 2004. PMID: 15306092 Review.
Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study.
Petersen P, Grind M, Adler J; SPORTIF II Investigators. Petersen P, et al. J Am Coll Cardiol. 2003 May 7;41(9):1445-51. doi: 10.1016/s0735-1097(03)00255-9. J Am Coll Cardiol. 2003. PMID: 12742279 Clinical Trial.
Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis.
van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Petersen P, Koudstaal PJ, Chang Y, Hellemons B. van Walraven C, et al. JAMA. 2002 Nov 20;288(19):2441-8. doi: 10.1001/jama.288.19.2441. JAMA. 2002. PMID: 12435257
The reduction in ischemic stroke risk was similar in patients with paroxysmal AF (1.5 vs 4.7 events per 100 patient-years; HR, 0.32; 95% CI, 0.16-0.61; P<.001). ...
The reduction in ischemic stroke risk was similar in patients with paroxysmal AF (1.5 vs 4.7 events per 100 patient-years; HR, 0.32; 95% CI, …
A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin.
van Walraven C, Hart RG, Wells GA, Petersen P, Koudstaal PJ, Gullov AL, Hellemons BS, Koefed BG, Laupacis A. van Walraven C, et al. Arch Intern Med. 2003 Apr 28;163(8):936-43. doi: 10.1001/archinte.163.8.936. Arch Intern Med. 2003. PMID: 12719203 Clinical Trial.
[Bleeding complications in oral anticoagulant treatment].
Gulløv AL, Koefoed BG, Petersen P. Gulløv AL, et al. Nord Med. 1995;110(4):114-8. Nord Med. 1995. PMID: 7724354 Review. Danish.
1,184 results
Jump to page
Feedback